Exchange: NASDAQ·Updated 07:52 PM EDT

SNY News

News
all
press releases
"Very Concerning Safety Issues": Trump's mRNA-Skeptic FDA Drug Chief Was Mysteriously Fired - Right Before This Drug Was Approved
"Very Concerning Safety Issues": Trump's mRNA-Skeptic FDA Drug Chief Was Mysteriously Fired - Right Before This Drug Was Approved Within three months of firing Tracy Beth H?eg, its top drug regulator, the FDA had approved the first mRNA flu shot, cleared a Sanofi diabetes treatment...
Zero Hedge
"Very Concerning Safety Issues": Trump's mRNA-Skeptic FDA Drug Chief Was Mysteriously Fired - Right Before This Drug Was Approved
"Very Concerning Safety Issues": Trump's mRNA-Skeptic FDA Drug Chief Was Mysteriously Fired - Right Before This Drug Was Approved Within three months of firing Tracy Beth H?eg, its top drug regulator, the FDA had approved the first mRNA flu shot, cleared a Sanofi diabetes treatment...
Zero Hedge
More News
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.
Stocktwits
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.
Zacks
Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights
Sanofi and Regeneron are broadening their immunology pipeline while keeping their existing Dupixent economics intact.
Stocktwits
Sanofi & Regeneron Expand Alliance With Four Next-Gen Antibodies
(RTTNews) - On Thursday, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced the expansion of their global collaboration to develop and commercialize four next-generation, long-acting immunology antibodies targeting type 2 inflammation...
Nasdaq News: Markets
Teva's Branded Drugs Take Center Stage in Its Growth Strategy
Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.
Zacks
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?
GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.
Zacks
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.
Zacks
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going
Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.
Zacks
Full Transcript: Sanofi Q2 2026 Earnings Call
Sanofi (NASDAQ:SNY) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earningsread more...
Benzinga

Advertisement|Remove ads.